Department of Health and Human Services
Part 1. Overview Information

 

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Cancer Institute (NCI)

Funding Opportunity Title

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24)

Activity Code

U24 Resource-Related Research Projects – Cooperative Agreements

Announcement Type

New

Related Notices

None

Funding Opportunity Announcement (FOA) Number

RFA-CA-17-039

Companion Funding Opportunity

RFA-CA-17-038, UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement  

Catalog of Federal Domestic Assistance (CFDA) Number(s)

 93.353 93.394

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) Program will provide an evidence base for multilevel interventions that increase rates of colorectal cancer (CRC) screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of CRC on the United States (U.S.) population.

The ACCSIS Program will support a U24 Coordinating Center (under this FOA) and UG3/UH3 phased award research projects (companion RFA-CA-17-038).

The ACCSIS Coordinating Center will facilitate coordination across the ACCSIS Research Projects (UG3/UH3 phased award supported under companion RFA-CA-17-038); provide administrative support to the ACCSIS Program; assist with identification and collection of common data elements; support the evaluation of locally-developed innovative approaches to increase CRC screening, follow-up, and referral-to-care rates; and develop and coordinate data sharing plans.

Key Dates

 

Posted Date

October 20, 2017

Open Date (Earliest Submission Date)

December 18, 2017

Letter of Intent Due Date(s)

December 18, 2017

Application Due Date(s)

January 18, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

No late applications will be accepted for this FOA.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not Applicable

Scientific Merit Review

May 2018

Advisory Council Review

August 2018

Earliest Start Date

September 2018

Expiration Date

January 19, 2018

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.


There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.

  3. Go to Grants.gov to download an application package to complete the application forms offline or create a Workspace to complete the forms online; submit your application to Grants.gov; and track your application in eRA Commons.
Learn more about the various submission options.

Table of Contents

Part 1. Overview Information
Part 2. Full Text of the Announcement

Section I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information


Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Purpose

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) Program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population.

The ACCSIS Program is comprised of two Funding Opportunity Announcements (FOAs) that solicit applications for:

  • ACCSIS Coordinating Center (this FOA); and
  • ACCSIS Research Projects (companion RFA-CA-17-038).

The overall goal of the ACCSIS Program is to provide national leadership on advancing the science on how best to increase the adoption, implementation, and sustainability of evidence-based practices, programs, and interventions to increase rates of CRC screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. The ACCSIS Program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up nationwide to reduce the burden of CRC cancer on the U.S. population.

Key Definitions for this FOA:

  • ACCSIS Program: Refers to the combined effort of the ACCSIS Research Projects, ACCSIS Coordinating Center, and the NCI to advance the science of implementation of multilevel interventions to increase rates of CRC screening, follow-up, and referral-to-care.
  • ACCSIS Program Steering Committee: Includes representatives from the ACCSIS Coordinating Center, each ACCSIS Research Project, and the NCI.
  • ACCSIS Coordinating Center: Includes the coordinating center funded through the companion RFA-CA-17-039.
  • ACCSIS Research Projects: Includes UG3 Planning-Exploratory Phase and the UH3 Implementation Phase research projects funded through this FOA.
  • UG3 Planning-Exploratory Phase: One-year Planning-Exploratory Phase during which research teams are expected to pilot test, measure, and refine the multilevel intervention in preparation for the experimental or quasi-experimental trial in the UH3 Implementation Phase.  
  • UH3 Implementation Phase: Two- to four-year Implementation Phase during which research teams are expected to conduct an experimental or quasi-experimental study to test the impact of a multilevel intervention on increasing rates of CRC screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards.  
  • Multilevel Intervention: An intervention that includes multiple components that target change at two or more levels of individuals, healthcare or public health providers, or healthcare/community settings, and that measures outcomes at two or more levels. Selection of multilevel intervention components across different levels should be guided by relevant theories, models, or frameworks; a review of the extant literature; and local assessment of barriers and facilitators, and should include a priori hypotheses of how components are expected to affect each other, as well as inform the selection and measurement of proposed outcome(s).

            Levels include:

  • Individuals: Individuals who receive or are the target of receiving CRC screening, follow-up, and referral-to-care services as well as those who are directly involved in supporting such individuals in their receipt of CRC screening, follow-up, and referral-to-care services. Examples but are not limited to include patients, caregivers, and family members.
  • Healthcare or public health providers: Healthcare or public health providers. Examples include but are not limited to physicians, nurse practitioners, community health workers, and patient navigators involved in delivering healthcare practices, programs, interventions, and other health-focused services to individuals.
  • Healthcare and/or community settings: Organization(s) in which individuals receive health-focused services across the cancer care continuum. Examples include but are not limited to clinics (e.g., primary care, specialty care), hospitals, cancer centers, federally qualified health centers, integrated delivery systems, health departments, and community-based organizations.
  • Experimental Study Design: Study design that includes manipulation (i.e., exposure to at least one intervention), randomization, and a control group. Studies must include prospective randomized to one or more experimental condition(s) (i.e., multilevel intervention) and include a control condition (e.g., standard-of-care, comparison condition, time-attention control). Examples of experimental study designs include randomized controlled trials, cluster randomized controlled trials, group randomized controlled trials, pragmatic randomized controlled trials, and stepped-wedge cluster randomized controlled trials. 
  • Quasi-Experimental Study Design: Study design that includes manipulation (i.e., exposure to at least one intervention), no randomization, and a control group. Studies must include prospective exposure to an experimental condition (i.e., multilevel intervention) and include a control condition (e.g., standard-of-care, comparison condition, time-attention control). Examples of quasi-experimental study designs include interrupted time series, regression discontinuity, and nonequivalent control group.
Background

NCI convened the Blue Ribbon Panel (BRP) in 2016 to provide recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer research in 5 years, now called the Beau Biden Cancer MoonshotSM Initiative. The BRP was charged with assessing the state-of-the-science in specific areas and identifying major research opportunities that could uniquely benefit from the support of the Cancer Moonshot and could lead to significant advances in our understanding of cancer and in how to intervene in its initiation and progression. The recommendations focused on areas in which a coordinated effort could profoundly accelerate the pace of progress in the fight against cancer and were not intended to replace existing cancer programs, initiatives, and policies already underway. The BRP final report was approved by the National Cancer Advisory Board and included a recommendation for a strategic investment in the development and testing of implementation strategies to significantly improve CRC screening, follow-up, and referral-to-care, particularly among underserved populations. The 21st Century Cures Act was signed into law in December 2016 dedicating new funds to support efforts associated with the Beau Biden Cancer MoonshotSM Initiative, including support for this FOA.

Challenges Associated with CRC Screening. CRC is the second leading cause of cancer deaths in the U.S., and screening is a major factor with a documented potential for decreasing CRC mortality rates. However, the current U.S. screening rate is below 50%, and almost 30% of eligible adults have never been screened for CRC. These rates are well below the national goals set by the National Colorectal Cancer Roundtable (NCCRT; 80% by 2018) and by Healthy People 2020 (70.5%). In addition to CRC screening, rates for appropriate CRC follow-up and referral-to-care (e.g., additional tests, diagnosis, treatment, active surveillance, watchful waiting, survivorship, where indicated) are suboptimal. Among traditionally underserved and marginalized populations, such as those residing in rural areas, racial and ethnic minority populations, and low-income populations, rates for CRC screening, follow-up, and referral-to-care are particularly low relative to other target populations, although rates collectively remain well below the national target.   

Current Approaches to Increase CRC Screening. Currently, there exist many evidence-based tests, practices, programs, interventions, and approaches demonstrated to reduce CRC-related mortality, including those related to CRC screening, follow-up, and referral-to-care. Recommended CRC screening tests include fecal occult blood testing (FOBT), guaiac-fecal occult blood test (gFOBT), fecal immunochemical test (FIT), flexible sigmoidoscopy, and colonoscopy. To promote uptake of these screening tests, more than fifteen evidence-based interventions are available (see NCI's Research-Tested Interventions Programs [RTIPs] for details). These interventions have been developed to increase CRC screening rates for many target populations (e.g., American Indians/Alaska Natives, Asians/Pacific Islanders, Blacks/African Americans, Hispanics/Latinos, Native Hawaiians, low-income populations, and rural populations) using various delivery modes (e.g., telephone calls, mailed brochures, educational sessions, patient navigation), and across delivery settings (e.g., community-based organizations, faith-based organizations, clinical care). Researchers have also identified ways to increase the adoption and appropriate use of evidence-based interventions among patients, providers, teams, organizations, communities, and systems of care. Dozens of implementation strategies have been identified in the literature; examples include supervision, technical assistance, coaching, payment/financing, training, champions, leadership training, organizational change interventions, learning collaboratives, audit and feedback, and partnerships.

Multilevel Interventions to Increase CRC Screening. Efforts to increase rates of CRC screening, follow-up, and referral-to-care have mostly focused on developing and testing single-level interventions (i.e., those targeting change at one level, such as patients, providers, or clinics/organizations). However, single-level interventions are often insufficient to lead to sustained change in CRC screening, follow-up, and referral-to-care rates. To have a significant impact on reducing CRC-related mortality, multilevel interventions are needed to increase the adoption and appropriate use of evidence-based CRC screening, follow-up, and referral-to-care interventions. Multilevel interventions are those that address two or more levels of change, which may include patient-level barriers (e.g., access to care, cost, lack of awareness, fear of results), provider-level barriers (e.g., unfamiliarity with clinical guidelines, limited shared decision-making skills, competing demands), and/or clinic/system/organizational-level barriers (e.g., poor organizational culture and climate, lack of systematic or electronic reminder systems). Essential to this multilevel approach is the explicit description of a priori hypotheses. These hypotheses address how proposed multilevel intervention components are expected to affect each other, as well as how multilevel intervention components will affect the desired outcome(s). Hypotheses, mechanisms of change, and intended impact on outcomes should be informed by relevant frameworks, models, or theories.

Recommendations of Cancer Moonshot Blue Ribbon Panel: To address the population impact of suboptimal rates for CRC screening and follow-up care, the Cancer MoonshotSM Blue Ribbon Panel Implementation Science Working Group recommended a strategic investment in the development and testing of implementation strategies to significantly improve CRC screening and follow-up rates, particularly among traditionally underserved populations. Specifically, the working group recommended research to: 1) identify, understand, and develop multilevel interventions for increasing CRC screening and follow-up of positive test results; and 2) disseminate effective multilevel interventions to other CRC programs. The workgroup noted that this research could help to accelerate the implementation of additional population-level cancer prevention and control recommendations.

 
Research Objectives and Main Requirements

This FOA supports one ACCSIS Coordinating Center that will assist and support the ACCSIS Research Projects funded under the companion RFA-CA-17-038. Applicants responding to the ACCSIS Coordinating Center FOA are expected to familiarize themselves with the companion FOA (RFA-CA-17-038) and the requirements for the UG3/UH3 projects as it relates to activities and responsibilities required of ACCSIS Coordinating Center.

Main Scientific Responsibilities of ACCSIS Coordinating Center

  • Assist ACCSIS Research Projects in pilot testing, refining, and assessing the impact of a multilevel intervention on rates of CRC screening, follow-up, and referral-to-care. Support activities may include (but are not limited to) technical support, selection and harmonization of measures across ACCSIS Research Projects, refinement of the multilevel intervention, review of extant literature, facilitation and coordination of stakeholder partnerships, and guidance on study design and methods;
  • Coordinate collaboration across all ACCSIS Research Projects in the selection, harmonization, collection, and analysis of common data measures and elements as well create public data sets for all data collected across all ACCSIS Research Projects to be made accessible after study completion and in accordance with procedures under the Beau Biden Cancer MoonshotSM Program;
  • Support ACCSIS Research Projects in the identification and evaluation of local practices, programs, and/or interventions on rates of CRC screening, follow-up, and referral-to-care. Such local practices, programs, and/or interventions will be identified and evaluated in addition to (but separate from) the main experimental or quasi-experimental study proposed during the UH3 Implementation Phase of each ACCSIS Research Project;
  • Collect, synthesize, and disseminate main findings and lessons learned from the ACCSIS Research Projects. Such activities may include (but are not limited to) collection of multilevel intervention materials, development of implementation manuals, development of user-friendly study summaries tailored for different stakeholder audiences (e.g., patient groups, healthcare providers, policymakers), presentations at conferences and professional meetings, interactive webinars, and distribution of study summaries and materials via other communication channels (e.g., social media, Twitter, newsletters, etc.). The ACCSIS Coordinating Center will also be expected to collect, clean, harmonize, merge (where appropriate), and compile data from each ACCSIS Research Project into a central, searchable, user-friendly data repository that will be made accessible to the research community upon study completion.

ACCSIS Coordinating Center Research Team Expertise and Composition

To fulfill the four main responsibilities stated above, the ACCSIS Coordinating Center team will be expected to have appropriate expertise and experience in such areas as:

  • Development and testing of multilevel interventions to increase rates of CRC screening, follow-up, and referral-to-care;
  • Experience with cancer health disparities research, including but not limited to patient and stakeholder engagement, culturally-sensitive interventions, and targeted recruitment and enrollment strategies for underserved populations; 
  • Ethical and regulatory requirements for conducting single or multi-site experimental or quasi-experimental trials involving patients, providers, organizations, and/or systems of care;
  • Extensive knowledge of evidence base for multilevel intervention components to increase rates of CRC screening, follow-up, and referral-to-care as well as other relevant health areas that may be applicable to the proposed ACCSIS Research Projects;
  • Successful partnerships with multiple study teams across diverse settings and regions in the design, implementation, and completion of large research studies;
  • Knowledge of established as well as innovative strategies for increasing and sustaining use of evidence-based practices and programs in health settings, including but not limited to novel payment or reimbursement models, theory-based implementation strategies, multi-stakeholder partnerships, health information technology, and patient-centered research;
  • Collaborative engagement with relevant stakeholder groups, including but not limited to patients, providers, clinics, health departments, hospitals, integrated delivery systems, federally qualified health centers, and community-based organizations;
  • Multilevel data collection, harmonization, analysis, and data repository in public domains;
  • Experimental and quasi-experimental study designs;
  • Longitudinal and multilevel data collection and analysis;
  • Qualitative, quantitative, and mixed methods study designs, data collection, and analysis;
  • Development of user-friendly materials (e.g., training manuals, brochures, flyers, newsletters), and ability to leverage various communication channels to share information to target end-users;
  • Creativity and demonstrated success in anticipating and solving challenges (i.e., technical, personnel, logistical, timelines) in ways that promote engagement among all participants and timely accomplishments of objectives.

The composition of the research team for the proposed ACCSIS Coordinating Center must ensure the requisite expertise in CRC screening, follow-up, and referral-to-care. In addition, the team should be capable of effective communications and productive collaborations with various stakeholder groups. Therefore, the team is expected to include senior members who have considerable leadership skills and experience in productive collaborations with large research teams and/or multi-stakeholder groups (e.g., clinics, health departments, community-based organizations, hospitals) in diverse settings (e.g., rural, urban).

Logistical and Administrative Responsibilities of ACCSIS Coordinating Center

In addition to scientific support of the ACCSIS Research Programs, and ACCSIS Coordinating Center contributions, the proposed ACCSIS Coordinating Center must be able to provide logistical and administrative support to ACCSIS Research Projects and joint trans-network activities, including but not limited to:

  • Provision of a public website for communication and sharing of activities, events, and resources of the program;
  • Organizational and logistical support for facilitating the activities of the ACCSIS Work Groups and ACCSIS Program Steering Committee;
  • Supporting standards and mechanisms for publicly sharing data, resources, and code developed and utilized in the ACCSIS Research Projects and by the ACCSIS Coordinating Center;
  • Organizing and supporting the logistics of annual ACCSIS Program Steering Committee meetings in the Bethesda, Maryland, area.

ACCSIS Trans-Program Activities

The ACCSIS Coordinating Center will be required to interact closely with ACCSIS Research Projects and participate in other ACCSIS Program activities outlined below.

  • Scientific Interactions with ACCSIS Research Projects. The ACCSIS Coordinating Center will collaborate with each ACCSIS Research Project to pilot test and refine the proposed multilevel intervention; finalize the multilevel intervention to be tested; develop common data elements and measures to be used in ACCSIS Research Projects; collaborate on writing scientific manuscripts; identify, monitor, and evaluate locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care; and incorporate scientific expertise and input on the design, conduct, and analysis of the experimental or quasi-experimental study to test the impact of a multilevel intervention on rates of CRC screening, follow-up, and referral-to-care.
  • ACCSIS Work Groups. ACCSIS Work Groups will be established by the ACCSIS Program Steering Committee (described below). Members of the ACCSIS Work Groups will include investigators from the ACCSIS Coordinating Center, ACCSIS Research Projects, and the NCI. Work Groups are intended to provide a forum for discussing and advising on topics areas that overlap all ACCSIS Research Projects. In is anticipated that Work Groups will be established in the following 4 areas: (1) Implementation Science, (2) Healthcare Systems/Community Partnerships, (3) Ethics/Regulatory/Data Sharing, and (4) Design/Analysis

ACCSIS Program Steering Committee

An ACCSIS Program Steering Committee will be established as the governing board of the ACCSIS Program. For details on the composition and responsibilities of the Steering Committee, see Section VI.2 under Cooperative Agreement Terms and Conditions of the Award.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information
Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed

New
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

Funds Available and Anticipated Number of Awards

NCI intends to commit $600,000 in FY 2018 to fund one award.

Award Budget

 Budget is limited to $400,000 in direct costs per year.

Award Project Period

  The maximum project period is 5 years. 

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.

Section III. Eligibility Information
1. Eligible Applicants
Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

o   Hispanic-serving Institutions

o   Historically Black Colleges and Universities (HBCUs)

o   Tribally Controlled Colleges and Universities (TCCUs)

o   Alaska Native and Native Hawaiian Serving Institutions

o   Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Governments

  • State Governments
  • County Governments
  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are  allowed.

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) (formerly CCR) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM. 
  • eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

 An individual designated as a PD/PI on the ACCSIS Research Projects application (for RFA-CA-17-038) is not eligible for serving as a PD/PI on the ACCSIS Coordinating Center application submitted in response to this FOA.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility
Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time.  This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).
Section IV. Application and Submission Information
1. Requesting an Application Package

Buttons to access the online ASSIST system or to download application forms are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the Research (R) Instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to:

Sarah Kobrin, Ph.D.
National Cancer Institute
Telephone: 240-276-6931
Fax: 240-276-7906
Email: kobrins@mail.nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed, with the following exceptions or additional requirements:

  • For this specific FOA, the Research Strategy is limited to 30 pages.
Instructions for Application Submission

The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.

SF424(R&R) Cover

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Project/Performance Site Locations

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Other Project Information

All instructions in the SF424 (R&R) Application Guide must be followed.  

SF424(R&R) Senior/Key Person Profile

All instructions in the SF424 (R&R) Application Guide must be followed. 

Biosketches should reflect the PD(s)/PI(s) and key personnel's expertise in CRC screening, follow-up, and referral-to-care, health services or healthcare delivery research, multilevel interventions, experimental and quasi-experimental research designs, and implementation science. Demonstrated collaboration with research, practice, and policy stakeholder groups as well as leadership and effective management of complex research projects should also be described.  

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

The contact PD/PI must commit a minimum of 2.4 person-months effort per year to the project. The commitment cannot be reduced in later years of the award. If a project includes multiple PDs/PIs, the total annual PD/PI effort must be at least 2.4 person-months and the contact PD/PI effort must be a minimum or 1.8 person-months.

Budgeted effort of other personnel must be appropriate to the needs and objectives of the project.

Applications must include a travel budget for several key personnel (e.g., PD[s]/PI[s], program manager, and one or two investigators) to attend an annual 2-day meeting of the ACCSIS Steering Committee for the duration of the ACCSIS program. Meetings will take place in the Bethesda, Maryland, area.

R&R Subaward Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the SF424 (R&R) Application Guide must be followed.  

PHS 398 Research Plan

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions: 

Specific Aims: Outline the general objectives of the proposed ACCSIS Coordinating Center, the overall approach for achieving these goals, and how approach will support Research Projects.

Research Strategy: The Research Strategy section must consist of Subsections A-D, as explained below.

Subsection A: Administrative Processes

  • Explain the collective capabilities of the study team in terms of their qualifications and experiences in coordinating large, multisite research initiatives, and their qualifications in conducting research in CRC screening, follow-up, and referral-to-care in health settings. Emphasize how the combined, interdisciplinary expertise of the team will meet the needs of the ACCSIS Coordination Center activities. Do not repeat information provided in biosketches;
  • Describe the organizational and governing structure for the ACCSIS Coordinating Center, lines of authority, and decision-making processes.

Subsection B: Common Data Elements

Propose a process for interacting with the ACCSIS Research Projects and the NCI to develop standardized frameworks and measures to assess: (1) CRC screening, follow-up, and referral-to-care rates of the target populations; (2) multilevel factors that may be associated with the screening process; (3) the characteristics of multilevel intervention to be tested in the trials; and (4) multilevel outcomes. Include a discussion of:

  • The collective expertise and qualifications of the study team in assessing the four major domains of measurement (do not repeat information already provided in biosketches);
  • Vision and rationale for key data to be collected across the domains of interest in CRC screening implementation;
  • A proposed process and timeline for incorporating and harmonizing data captured by individual projects into a broader context that cuts across target populations and settings.

Subsection C: Evaluation of Locally-Developed Innovative Approaches

Propose a process for supporting ACCSIS Research Projects in identifying, monitoring, and evaluation of locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care. Include a discussion of:

  • Vision for the types of research projects that could be conducted within each Research Project;
  • Proposed approach to the solicitation and review of proposals to identify, monitor, and evaluate locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care;
  • Proposed process and timeline for the solicitation, prioritization, selection, and conduct (including data analysis) of locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care.

Subsection D: Data Sharing and Dissemination

Provide a detailed plan for how data from each ACCSIS Research Project will be collected, cleaned, merged, and collated into a data repository accessible to the research community upon completion of the overall project. Plans should include steps for creating a user-friendly data repository, standard operating procedures, accessibility requirements, review process for granting access to the research community, data codebook, and guidance documents for data analyses. The data repository and requisite information should include both qualitative and quantitative data from each ACCSIS Research Project, where applicable, for both process and outcome variables across all data collection timepoints. 

Propose a process for sharing results from the ACCSIS Program to stakeholder groups to influence CRC screening, follow-up, and referral-to-care practices nationwide. Include a discussion of:

  • Vision for the types of stakeholders to be reached;
  • Proposed approach to synthesizing and transmitting research evidence from the program;
  • Proposed process for evaluating the impact of dissemination efforts.

Health Disparities. If applicable to the type of research being proposed, address how health disparity populations or data will be integrated into the proposed studies. Highlight, as relevant, any opportunities that, if implemented, can reduce the burden of cancer in the health disparities that currently exist.  In this context, efforts are encouraged to address the needs of racially/ethnically diverse populations and those from urban and rural areas who are poor and medically underserved, who continue to suffer disproportionately from certain cancers and have higher morbidity and mortality rates.

Letters of Support:

Include letters of support from participating institutions and organizations who must agree to adopt and implement the proposed Resources and Data Sharing Plans. 

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

  • All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.
  • Addressing the Cancer Moonshot Public Access Pilot Program: Utilizing the provision outlined in the 21st Century Cures Act, NCI has established a data sharing policy for projects that are funded as part of the Beau Biden Cancer MoonshotSM Initiative that requires applicants to submit a Public Access and Data Sharing Plan that: (1) describes their proposed process for making resulting Publications and to the extent possible, the Underlying Primary Data immediately and broadly available to the public; (2) if applicable, provides a justification to NCI if such sharing is not possible. NCI will give competitive preference and funding priority to applications with a data sharing plan that complies with the strategy described here. The data sharing plan will become a term and condition of award.
  • In addition, the ACCSIS Program encourages sharing of resources with broad availability of policies, practices, materials, and tools to facilitate collaboration, transparency, and reproducibility. The ACCSIS Program encourages sharing of study data from ACCSIS Research Projects in a timely manner with appropriate privacy and confidentiality protections to facilitate further research, reuse of data, and replication. Thus, the ACCSIS Program expects grantees to implement a Resources and Data Sharing Plan consistent with achieving these program goals. 
  • Guiding Principles for Cancer Moonshot Biobanking Activities: The goal in developing these guiding principles is to accelerate research by a) increasing the availability of biospecimens for Cancer Moonshot-related and other biomedical research through facilitation of investigator to investigator sharing of biospecimens, and b) increasing the reproducibility of Cancer Moonshot research through improved biospecimen practices and corresponding annotation. These guiding principles also seek to facilitate, where possible, increased engagement of research participants through researchers' communication of aggregate research results and, in some cases, individual genomic findings that may be medically actionable for research participants. NCI will give competitive preference and funding priority to applications that conform to the "Guiding Principles for Cancer Moonshot Biobanking Activities" (http://biospecimens.cancer.gov/programs/cancermoonshot/principles) and are consistent with the "2016 NCI Best Practices for Biospecimen Resources" (https://biospecimens.cancer.gov/bestpractices/).

Appendix:

Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.

PHS Inclusion Enrollment Report

When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.

PHS Assignment Request Form

All instructions in the SF424 (R&R) Application Guide must be followed. 

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by the NCI, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy.

Section V. Application Review Information
1. Criteria

Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

 Significance

How well does the proposed ACCSIS Coordinating Center address the needs of the research projects that it will coordinate? Is the scope of activities proposed for the ACCSIS Coordinating Center appropriate to meet those needs? Will successful completion of the aims bring unique advantages or capabilities to the research projects?

Specific to this FOA:

Will the ACCSIS Coordinating Center provide national leadership and engage all stakeholders in advancing policies and practices that enhance the broad participation of researchers and healthcare systems in testing implementation strategies for CRC screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards? If the aims of the center are achieved, how will translation of research into practice, and participation among healthcare delivery organizations in research activities, be improved?

Investigator(s)

Are the PD(s)/PI(s) and other personnel well suited to their roles in the ACCSIS Coordinating Center? Do they have appropriate experience and training, and have they demonstrated experience and an ongoing record of accomplishments in managing implementation research in cancer control? Do the investigators demonstrate significant experience with coordinating collaborative clinical research? If the ACCSIS Coordinating Center is multi-PD/PI, do the investigators have complementary and integrated expertise and skills; are their leadership approach, governance, plans for conflict resolution, and organizational structure appropriate for the Center? Does the applicant have experience overseeing selection and management of sub-awards, if needed?  

Specific to this FOA:

Do the personnel have the appropriate breadth of expertise and experience, including but not limited to, data extraction from electronic health records and other clinical systems, ethical issues related to research and healthcare boundaries, design, conduct, and analysis of research studies, implementation science projects, and collaborative research with a variety of stakeholders? Are the proposed leadership approach, staffing, governance, and organizational structure appropriate for the project? Are the investigators willing to collaborate with the NCI and ACCSIS Research Project awardees to meet the goals and objectives of this program? How well does the application describe how the investigative team is up-to-date on the changing landscape of healthcare systems research and participant protection regulations?

Innovation

Does the application propose novel organizational concepts, management strategies, or instrumentation in coordinating the research projects the Center will serve? Are the concepts, strategies, or instrumentation novel to one type of research program or applicable in a broad sense? Is a refinement, improvement, or new application of organizational concepts, management strategies or instrumentation proposed?   

Specific to this FOA:

Does the application include mechanisms for leveraging novel collaboration and communication strategies? Does the application indicate creativity and flexibility to innovate on an ongoing basis, particularly in the study of locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care?

Approach

Are the overall strategy, operational plan, and organizational structure well-reasoned and appropriate to accomplish the goals of the research projects the ACCSIS Coordinating Center will serve? Will the investigators promote strategies to ensure a robust and unbiased scientific approach across the projects, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the projects are in the early stages of operation, does the proposed strategy adequately establish feasibility and manage the risks associated with the activities of the projects? Is an appropriate plan for work-flow with a well-established timeline proposed? Have the investigators presented adequate plans to ensure consideration of relevant biological variables, such as sex, for studies of vertebrate animals or human subjects?

Specific to this FOA: 

Does the application contain acceptable plans for addressing the NCI Cancer MoonshotSM Public Access and Data Sharing Policy? Will the proposed approach allow efficient management upkeep of a public website? Will the proposed approach allow for the ACCSIS Coordinating Center personnel and collaborative tools to enable speedy ACCSIS Research Project planning and implementation? Are the plans for administrative and logistical support of the ACCSIS Program appropriate and well-aligned with scientific support for ACCSIS Research Projects?

Environment

Will the institutional environment in which the ACCSIS Coordinating Center will operate contribute to the probability of success in facilitating the research projects it serves? Are the institutional support, equipment and other physical resources available to the investigators adequate for the ACCSIS Coordinating Center proposed? Will the ACCSIS Coordinating Center benefit from unique features of the institutional environment, infrastructure, or personnel? Are resources available within the scientific environment to support electronic information handling?

Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Children 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Not Applicable

Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Not Applicable

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3)  Genomic Data Sharing Plan (GDS).

Authentication of Key Biological and/or Chemical Resources:

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the CSR, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

  • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  • Will receive a written critique.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Cancer Advisory Board. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.
3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information
1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee's business official.

Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General  and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency.  HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements.  FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award.  An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS.  The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant's integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 "Federal awarding agency review of risk posed by applicants."  This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH, as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • Leading the development of common data elements and use of measures/instruments across the ACCSIS Research Projects;
  • Implementing a process for supporting each ACCSIS Research Project in the development, approval, and conduct of research with respect to studying locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care in
  • Overseeing the conduct of data analysis in support of ACCSIS Research Projects;
  • Developing and implementing a process to support the sharing of ACCSIS Research Project data with qualified investigators who are not part of the ACCSIS Program;
  • Serving as voting member(s) on the ACCSIS Program Steering Committee;
  • Coordinating site visits with ACCSIS Research Projects and NCI Project Scientists, as needed;
  • Collecting and summarizing updates on progress and problems across the ACCSIS Research Projects;
  • Implementing guidelines and procedures developed by the ACCSIS Program Steering Committee;
  • Participating in teleconferences with the NCI;
  • Assuring that appropriate administrative and logistical support is provided to coordinate activities and collaboration across the ACCSIS Research Projects (including but not limited to ACCSIS Work Groups, teleconferences, and meetings); and  
  • Attending annual ACCSIS Program Steering Committee meetings to be held in the Bethesda, Maryland, area.

Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.

In addition to standard annual Research Performance Progress Report (RPPR) submissions, Principal Investigators may be expected to supply additional progress-related information.

Additional responsibilities include:

  • Leveraging, where feasible, technology from related NCI-sponsored informatics initiatives, for example The NCI Informatics Technology for Cancer Research (ITCR) program, which supports the development of informatics algorithms, tools, and resources across the continuum of cancer research.
  • Coordinating with and leveraging, where feasible, the technology of The NCI Cancer Research Data Commons, a program that will provide infrastructure to make diverse cancer research data broadly available and to maximize their reuse and impact (cbiit.cancer.gov/cancerdatacommons).
  • Meeting annually with other Cancer Moonshot U24 coordinating centers to help coordinate the sharing of data, research resources, tools/platforms, and access to newly established biorepositories across the Moonshot initiatives.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

One or more designated NCI Program staff members will have substantial involvement as Project Scientist(s) for the ACCSIS Program.

Additionally, an NCI Program Director acting as Program Official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. Program Officials may also have substantial programmatic involvement (as Project Scientists).

In carrying out its stewardship of Beau Biden Cancer Moonshot initiatives, the National Cancer Institute (NCI) will monitor and evaluate progress to meet the expectations set forth by Congress in the 21st Century Cures Act. 

The specific roles of the substantially involved NCI staff members include the following activities:

  • Participating as voting members in the ACCSIS Program Steering Committee;
  • Advising on innovative approaches for sharing results from the ACCSIS Program to key stakeholder organizations (e.g., professional societies, practice-based organizations, patient advisory groups) in user-friendly formats (e.g., briefs, summaries) that extend beyond the traditional peer-reviewed publications or scientific conference presentations;
  • Participating in teleconferences with the PDs/PIs and key personnel of ACCSIS Coordinating Center to monitor progress;
  • Attending annual ACCSIS Program Steering Committee meetings to be held in the Bethesda, Maryland, area;
  • Participating in ACCSIS Work Groups;
  • Providing scientific input on identifying, monitoring, and evaluating locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care conducted by each ACCSIS Research Project and supported by the ACCSIS Coordinating Center; and
  • Contributing, as appropriate, to scientific manuscripts and other scientific and scholarly activities (e.g., oral presentations, poster presentations) resulting from the ACCSIS Program.

Areas of Joint Responsibility include:

ACCSIS Program Steering Committee:

ACCSIS UG3/UH3 awardees funded under RFA-CA-17-038 and the U24 awardees funded under RFA-CA-17-039 will form, together with the NCI, the Steering Committee, which will serve as the main governing board of the ACCSIS Program. The ACCSIS Program Steering Committee will consist of the following voting members:

  • The PDs/PIs from each ACCSIS Research Project UG3/UH3 award (one vote per ACCSIS Research Project;
  • The PDs/PIs from the ACCSIS Coordinating Center (one vote for the ACCSIS Coordinating Center); and
  • The NCI-assigned Project Scientist(s) who collectively will have one vote.

A Chair of the ACCSIS Program Steering Committee will be selected at the first meeting. He/she will serve a term of 12-months.

The Steering Committee will meet as needed via phone conference and in person once every year, at locations selected by the Steering Committee in consultation with the NCI.

The Steering Committee may decide to establish sub-committees for specific purposes. The NCI Project Scientists will serve on such sub-committees, as they deem appropriate.

The main responsibilities of the ACCSIS Program Steering Committee will include the following elements:

  • Addressing and coordinating aspects relevant to all ACCSIS Research Projects and the ACCSIS Coordinating Center;
  • Developing, as needed, overall policies and processes applicable to all ACCSIS awardees;
  • Assisting in dissemination across the ACCSIS Program of policies and processes that enable research in partnership with healthcare systems, their patients, and practitioners.
  • Attending annual meetings to review progress across the ACCSIS Research Projects;
  • Discussing approaches for supporting ACCSIS Research Projects in identifying, monitoring, and evaluating locally-developed innovative approaches to increase rates of CRC screening, follow-up, and referral-to-care;
  • Coordinating scientific writing groups for manuscripts and oral and poster presentations at professional societies and scholarly meetings;
  • Establishing ACCSIS Work Groups; and
  • Stimulating and coordinating communications among awardees, e.g., to share ideas, discuss solutions to technical issues, resolve logistical problems, etc.

Dispute Resolution:

Any disagreements that may arise in scientific and/or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting; one NIH designee; and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and HHS regulation 45 CFR Part 16.

3. Reporting

When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

In addition to standard RPPR awardees may be requested to supply additional progress-related information in the context of Beau Biden Cancer Moonshot initiative.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000.  See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Scientific/Research Contact(s)

For questions about the colorectal cancer screening and healthcare delivery system aspects of the application:

Sarah Kobrin, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6931
Email: kobrins@mail.nih.gov

For questions about the implementation science aspects of the application:

Wynne E. Norton, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6875
Email: wynne.norton@nih.gov

Peer Review Contact(s)

Robert Freund, Ph.D.
Center for Scientific Review (CSR)
Telephone: 301-435-1050
Email: freundr@csr.nih.gov

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.